证券代码：688393 证券简称：安必平 公告编号：2026-005 广州安必平医药科技股份有限公司 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经广州安必平医药科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实 现归属于母公司所有者的净利润-5,200.00万元到-4,200.00万元，与上年同期（法定披露数据）相比，将 出现亏损，减少7,329.13万元到6,329.13万元，同比减少344.23%到297.26%。 （2）预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净利润为-7,200.00万元 到-6,200.00万元，与上年同期（法定披露数据）相比，将减少8,625.38万元到7,625.38万元，同比减少 605.13%到534.97%。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：943.44万元。归属于母公司所有者的净利润：2,129.13万元。归属于母公司所有者的 扣除非经常性损益的净利润：1,425.38万元。 （二）每股收益：0.23元。 2025年年度业绩预亏公告 ...

安必平(688393.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润-5200万元到-4200 万元，与上年同期(法定披露数据)相比，将出现亏损，减少7,329.13万元到6,329.13万元，同比减少 344.23%到297.26%。 ...

智通财经APP讯，安必平(688393.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利 润-5200万元到-4200万元，与上年同期(法定披露数据)相比，将出现亏损，减少7,329.13万元到6,329.13 万元，同比减少344.23%到297.26%。 ...

报告期，公司营业收入同比下降，归属于上市公司股东的净利润同比下降，公司净利润预计为亏损状 态：（1）报告期公司营业收入下滑，主要受国家集中带量采购政策全面落地实施的影响，公司HPV产 品线因售价同比显著下降，导致该业务收入减少约4,650万元，同时，该产品线毛利率同步承压，毛利 同比减少约4,600万元。公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规 模。此外，为加速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，虽短期内对整体毛利产 生一定影响，但有效提升了客户覆盖效率。（2）为应对市场变化并构筑长期竞争优势，公司持续加强 产品研发创新力度，重点布局病理数智化及肿瘤伴随诊断产品领域，此举虽导致公司当期运营成本上 升，但为公司未来可持续发展奠定了坚实基础。 格隆汇1月30日丨安必平(688393.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母公 司所有者的净利润-5,200.00万元到-4,200.00万元，与上年同期（法定披露数据）相比，将出现亏损，减 少7,329.13万元到6,329.13万元，同比减少344.23%到297.26%。预计2025年年度实现归 ...

每经AI快讯，安必平1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利 润-5200万元到-4200万元，与上年同期相比，将出现亏损，减少7329.13万元到6329.13万元，同比减少 344.23%~297.26%。业绩变动主要原因是，主营业务影响。报告期，公司营业收入同比下降，归属于上 市公司股东的净利润同比下降，公司净利润预计为亏损状态：报告期公司营业收入下滑，主要受国家集 中带量采购政策全面落地实施的影响，公司HPV 产品线因售价同比显著下降，导致该业务收入减少约 4650万元，同时，该产品线毛利率同步承压，毛利同比减少约4600万元。公司主动优化业务结构，聚焦 主营业务收入拓展，相应减少代理产品业务规模。此外，为加速市场渗透，公司积极推进渠道策略调 整，扩大经销渠道比重，虽短期内对整体毛利产生一定影响，但有效提升了客户覆盖效率。为应对市场 变化并构筑长期竞争优势，公司持续加强产品研发创新力度，重点布局病理数智化及肿瘤伴随诊断产品 领域，此举虽导致公司当期运营成本上升，但为公司未来可持续发展奠定了坚实基础。基于谨慎性原 则，公司对截至2025年12月31日合并报表范围内的各类 ...

证券代码：688393 证券简称：安必平 公告编号：2026-005 广州安必平医药科技股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经广州安必平医药科技股份有限公司（以下简称"公司"）财务部门 初步测算，预计 2025 年年度实现归属于母公司所有者的净利润-5,200.00 万元 到-4,200.00 万元，与上年同期（法定披露数据）相比，将出现亏损，减少 7,329.13 万元到 6,329.13 万元，同比减少 344.23%到 297.26%。 （2）预计 2025 年年度实现归属于母公司所有者扣除非经常性损益后的净利 润为-7,200.00 万元到-6,200.00 万元，与上年同期（法定披露数据）相比，将 减少 8,625.38 万元到 7,625.38 万元，同比减少 605.13%到 534.97%。 （三）本次业绩预告相关财务 ...

安必平公告，预计2025年年度实现归属于母公司所有者的净利润-5200万元到-4200万元，与上年同期相 比，减少7329.13万元到6329.13万元，同比减少344.23%到297.26%；预计实现归属于母公司所有者扣除 非经常性损益后的净利润为-7200万元到-6200万元，与上年同期相比，减少8625.38万元到7625.38万 元，同比减少605.13%到534.97%。上年同期归属于母公司所有者的净利润为2129.13万元。 ...

安必平公告称，预计2025年度归属于母公司所有者的净利润为 - 5200.00万元到 - 4200.00万元，同比减 少344.23%到297.26%；扣非净利润为 - 7200.00万元到 - 6200.00万元，同比减少605.13%到534.97%。主 要因国家集采政策使HPV产品线收入和毛利减少约4650万元、4600万元；业务结构优化、渠道策略调整 影响当期毛利；加大研发投入致成本上升；计提资产减值准备。此外，非经常性损益因参股公司投资收 益增加。 ...

Group 1 - The core point of the news is that Anbiping's stock price increased by 5.34% to 30.40 CNY per share, with a total market capitalization of 2.844 billion CNY as of the report date [1] - Anbiping, established on July 6, 2005, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with 79.72% of its revenue coming from self-produced products [1] - The company's revenue composition includes 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Anbiping, holding 850,000 shares, which represents 0.91% of the circulating shares [2] - The fund has achieved a year-to-date return of 14.68% and a one-year return of 34.59%, ranking 477 out of 8,847 and 3,667 out of 8,099 in its category, respectively [2] - Longcheng Consumption Value Mixed A has a total asset size of 474 million CNY and has generated a cumulative return of 291.29% since its inception on April 6, 2006 [2]

Group 1: Important Market News - The People's Bank of China and the National Financial Regulatory Administration announced that the minimum down payment ratio for commercial housing loans is adjusted to no less than 30% [1] Group 2: Industry Insights - Domestic commercial aerospace companies are advancing their IPO processes, with China Aerospace Science and Technology Corporation's subsidiary, Zhongke Yuhang, changing its listing guidance status to acceptance. The company aims to become the first commercial aerospace stock in China [2] - The satellite communication industry is projected to reach a market size of 200 to 400 billion yuan by 2030, with an annual compound growth rate of 10% to 28%. This sector is transitioning from "concept validation" to "scale application," driven by technological maturity and cost reduction [2] - Major internet companies in China, including Alibaba, ByteDance, and Tencent, are intensifying competition in AI application products. Alibaba's newly launched Qianwen APP aims to serve as a personal AI assistant, integrating various services within its ecosystem [3][4] - Alibaba's Qianwen APP achieved over 10 million downloads within seven days of its launch, making it the fastest-growing AI application, directly competing with ByteDance's Doubao [4] - The brain-computer interface sector is gaining traction, with significant investments and advancements. A startup, Merge Labs, raised $252 million in seed funding, indicating strong interest in this technology [5][6] - The global market for brain-computer interface medical applications is expected to reach $40 billion by 2030 and $145 billion by 2040, highlighting its potential in treating neurological disorders [6] Group 3: Company Updates - Rongbai Technology is under investigation by the China Securities Regulatory Commission for misleading statements regarding a major contract [7] - San Da Membrane announced a plan to reduce its shareholding by up to 996,040 shares, representing no more than 3% of its total share capital [7] - He Shi Eye Hospital's shareholder plans to reduce its stake by up to 310,610 shares, accounting for 1.97% of the total share capital [7] - Jinke Environment reported a planned reduction of up to 102,520 shares by a significant shareholder, representing 0.83% of the total share capital [7] - Wei Si Medical announced a plan to reduce its shareholding by up to 287,310 shares, which is 3% of its total share capital [8] - Sifangda's controlling shareholder plans to reduce its stake by up to 483,150 shares, while other executives also plan to sell portions of their shares [8] - Chuhuan Technology reported a planned reduction of up to 239,560 shares by its significant shareholders [8]